GLP1R and kidney disorder: Sodium–glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to reduce the incidence of cardiovascular and kidney disease in people with type 2 diabetes, ostensibly independent of their effects on blood glucose [1, 2].